B ALL
Clinical trials for B ALL explained in plain language.
Never miss a new study
Get alerted when new B ALL trials appear
Sign up with your email to follow new studies for B ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR-T cells take on stubborn leukemia after transplant in new trial
Disease control Recruiting nowThis study compares two treatments for patients with B-cell acute lymphoblastic leukemia who still have small amounts of cancer cells (minimal residual disease) after a stem cell transplant. One group receives a single infusion of their own genetically modified immune cells (CAR-…
Matched conditions: B ALL
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New CAR T-Cell booster aims to stop leukemia relapse
Disease control Recruiting nowThis study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…
Matched conditions: B ALL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
New CAR-T therapy aims to tackle tough childhood leukemia
Disease control Recruiting nowThis phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cel…
Matched conditions: B ALL
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New gene therapy injection shows promise for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
Dual-Target CAR T-Cells offer new hope for kids with relapsed leukemia
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not responded to standard treatments. Participants receive their o…
Matched conditions: B ALL
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B ALL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Engineered immune cells take aim at childhood leukemia in new trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New genetic tests could help kids avoid unnecessary transplants after CAR t
Knowledge-focused Recruiting nowThis pilot study tests whether regular, advanced genetic testing of blood and bone marrow can better monitor children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission from CAR T therapy. The goal is to distinguish who is cured by CAR …
Matched conditions: B ALL
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:57 UTC
-
New study tracks hidden dangers of CAR t therapy in kids
Knowledge-focused Recruiting nowThis study follows 100 children and young adults who received CAR T cell therapy to understand short- and long-term side effects like infections, slow blood cell recovery, and nerve problems. Researchers will check participants at 3, 6, 12, and 24 months after treatment. The goal…
Matched conditions: B ALL
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC